Atossa Genetics Files Again for IPO | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Almost one year to the day after pulling a planned initial public offering, Seattle-based Atossa Genetics has refiled with US regulators to go public.

In a Form S-1 filed Feb. 13 with the US Securities and Exchange Commission Atossa said it seeks to sell 1 million shares of its common stock at a price of between $5 and $7 per share, raising up to a little more than $8 million.

The company plans to list on the Nasdaq Capital Market under ticker symbol "ATOS."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.